Cite as: F. Yang *et al.*, *Science*
10.1126/science.abf6648 (2021).

Shared B cell memory to coronaviruses and other pathogens varies in human age groups and tissues

Fan Yang^{1*}, Sandra C. A. Nielsen¹, Ramona A. Hoh¹, Katharina Röltgen¹, Oliver Fabian Wirz¹, Emily Haraguchi¹, Grace H. Jean¹, Ji-Yeun Lee¹, Tho D. Pham^{1,2}, Katherine J. L. Jackson³, Krishna M. Roskin^{4,5,6}, Yi Liu⁷, Khoa Nguyen¹, Robert S. Ohgami⁸, Eleanor M. Osborne⁹, Kari C. Nadeau^{10,11}, Claus U. Niemann^{12,13}, Julie Parsonnet^{14,15}, Scott D. Boyd^{1,10*}

¹Department of Pathology, Stanford University, Stanford, CA 94305, USA. ²Stanford Blood Center, Stanford University, Stanford, CA 94305, USA. ³Garvan Institute of Medical Research, Darlinghurst, NSW 2010, Australia. ⁴Department of Pediatrics, University of Cincinnati, Cincinnati, OH 45229, USA. ⁵Division of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA. ⁶Division of Immunobiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA. ⁷Calico Life Sciences, South San Francisco, CA 94080, USA. ⁸Department of Pathology, University of California, San Francisco, CA 94143, USA. ⁹Sarah Cannon Cancer Center, Tennessee Oncology, Smyrna, TN 37167, USA. ¹⁰Sean N. Parker Center for Allergy and Asthma Research, Stanford University, Stanford, CA 94305, USA. ¹¹Division of Pulmonary, Allergy and Critical Care Medicine, Stanford University, Stanford, CA 94305, USA. ¹²Department of Anesthesia and Perioperative Care, University of California, San Francisco, CA 94143, USA. ¹³Department of Surgery, Division of Transplantation, University of California, San Francisco, CA 94143, USA. ¹⁴Department of Medicine, Stanford University, Stanford, CA 94305, USA. ¹⁵Epidemiology and Population Health, Stanford University, Stanford, CA 94305, USA.

*Corresponding author. Email: sboyd1@stanford.edu (S.D.B.); fyang90@stanford.edu (F.Y.)

Vaccination and infection promote the formation, tissue distribution, and clonal evolution of B cells, which encode humoral immune memory. We evaluated convergent antigen-specific antibody genes of similar sequences shared between individuals in pediatric and adult blood, and deceased organ donor tissues. B cell memory varied for different pathogens. Polysaccharide antigen-specific clones were not exclusive to the spleen. Adults had higher clone frequencies and greater class-switching in lymphoid tissues than blood, while pediatric blood had abundant class-switched convergent clones. Consistent with reported serology, pre-pandemic children had class-switched convergent clones to SARS-CoV-2 with weak cross-reactivity to other coronaviruses, while adult blood or tissues showed few such clones. The results highlight the prominence of early childhood B cell clonal expansions and cross-reactivity for future responses to novel pathogens.

The clonal identity of a B cell can be traced by the sequence of its B cell receptor (BCR), which determines its antigen specificity (1). Immunoglobulin (Ig) sequences are formed via irreversible variable, diversity, and joining (VDJ) gene segment rearrangement and can be diversified through somatic hypermutation (SHM) and class-switch recombination (CSR) (2). Convergent BCRs with high sequence similarity in individuals exposed to the same antigen reflect antigen-driven clonal selection and form shared immunological memory between individuals (3–5). It is still unclear, however, how B cell memory to different antigens distributes in human tissues and changes during an individual's lifespan.

Humoral immune responses can differ between children and adults, as seen in children utilizing more B cell clones to achieve neutralizing antibody breadth to human immunodeficiency virus 1 (HIV-1) (6). Children usually have milder disease following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection than adults (7–10), potentially due to differences of viral receptor expression and immune responses (11, 12). SARS-CoV-2-infected children, in contrast to adults, show lower antibody titers and more IgG specific for the spike (S) protein over the nucleocapsid (N) protein. The faster viral clearance and lower viral antigen loads in

children have been attributed to these differences (13). Whether B cell clones specific for coronaviruses and other pathogens differ between children and adults is unclear. Blood-based studies survey only a fraction of an individual's BCR repertoire. The lymph nodes, spleen, and gastrointestinal tract harbor greater numbers of B cells and are major sites for SHM and CSR (14, 15). Specialized responses in particular tissues have been reported, such as for polysaccharide antigen-specific B cells in functional splenic tissue (16, 17).

To study changes in antigen-specific B cell memory over the human lifespan and across tissues, we characterized convergent Ig heavy chain (IGH) repertoires specific to six common pathogens, and two viruses not encountered by the participants, Ebola virus (EBOV) and SARS-CoV-2, in pre-COVID-19 pandemic individuals. We analyzed 12 cord blood (CB) samples, 93 blood samples from 51 children aged 1 to 3 years (18), 114 blood samples from healthy human adults aged 17 to 87 years (18), and blood, lymph node, and spleen samples from eight deceased organ donors (table S1). Children were vaccinated for *Haemophilus influenzae* type b (Hib), *Pneumococcus pneumoniae* (PP), and tetanus toxoid (TT) at 2, 4, 6, and 12–15 months, had influenza virus (flu) vaccination and were very likely exposed to respiratory syncytial virus

(RSV) but were not vaccinated for *Neisseria meningitidis* (NM) (19). Adult vaccination histories were unknown. Convergent IGH were identified by clustering with pathogen-specific reference IGH (table S2) sharing IGHV and IGHJ gene segment usage, CDR-H3 length, and minimum 85% CDR-H3 amino acid sequence identity.

B cell clones fell into three groups: (i) naïve clones containing only unmutated IgM or IgD (unmutM/D); (ii) antigen-experienced IgM/D with median SHM over 1% and without class-switched members (mutM/D); and (iii) antigen-experienced clones with class-switched members (CS). As we hypothesized, CB samples showed the lowest convergent IGH frequencies, consistent with limited fetal pathogen or vaccine exposures (Fig. 1A). Convergent clones in children and adults were largely mutM/D or CS (Fig. 1A and fig. S1). In adult blood, convergent clones for Hib, NM, and RSV were predominantly mutM/D clones, whereas PP, TT, and flu clones were predominantly CS (fig. S2A). Adults over 45 years of age had elevated mutM/D B cell clone frequencies to NM, potentially from exposures preceding widespread NM vaccination (20). Surprisingly, children had higher frequencies than adults of CS convergent clones for Hib, PP, TT, and RSV (fig. S2B), with mutated IgM or IgD also found in these clones (Fig. 1B). Convergent clone frequency in children's blood was not significantly associated with vaccination timing (figs. S3 to S5 and table S3), indicating persistently elevated frequencies. Flu-specific convergent clone frequencies were comparable in children and adults (Fig. 1A), with age-related increases in IgG SHM potentially due to frequent exposures via vaccination or infection (Fig. 1C) (18).

To test whether low frequencies of CS convergent clones in adult blood reflect preferential localization of clones in lymphoid tissues, we analyzed the blood, spleen, mediastinal lymph nodes (MDLN), and mesenteric lymph nodes (MSLN) of eight adult deceased organ donors. Lymph nodes and spleen showed greater clonal sharing with each other compared to blood (fig. S6A), suggesting larger clone sizes in lymphoid tissues and limited recirculation. Each tissue was dominated by different clones (fig. S6B) and SHM correlated with the number of tissues a clone occupied (fig. S7), consistent with greater prior antigen exposure leading to wider tissue distribution (21). Convergent clones frequencies for Hib, NM, PP, TT, RSV, and flu were higher in adult lymph nodes and spleen than blood (Fig. 2A). Adult lymph nodes and child blood shared more convergent clones than adult and child blood, showing differing distributions of these clones in children and adults (Fig. 2B and fig. S8, $P = 0.0001181$, Fisher's exact test). B cells specific for bacterial capsular polysaccharides are reported to be enriched in the spleen, and splenectomized patients are vulnerable to these bacteria (16, 17). However, frequencies of convergent clones for Hib, NM, and PP are similar or higher in lymph nodes

than in spleen. Moreover, estimated B cell numbers are greater in human lymph nodes than spleen (22, 23), indicating that spleen is not the sole reservoir of these clones. Convergent IGH for polysaccharides were usually IgM or IgD, with some CS clones for PP in lymph nodes and spleen (Fig. 2C). Thus, memory to these antigens spans both a diversity of lymphoid tissues and of isotype expression.

Recent reports describe SARS-CoV-2 binding antibodies in pre-pandemic children's blood (12, 24). Such antibodies and other physiological distinctions are under investigation in adults and children (25) and could contribute to the generally milder COVID-19 disease in children. SARS-CoV-2 S-binding B cells in unexposed individuals have been analyzed in a former SARS-CoV patient (26), naïve B cells of healthy individuals (27), and memory B cells in pre-pandemic donors (26, 28). We detected rare convergent clones for EBOV, as unmutM/D in blood or tissues (Fig. 3A and fig. S9A). By contrast, convergent clones for SARS-CoV-2 (table S4) were more common in children's blood. In 37 of 51 children, these clones displayed SHM with or without CS, indicating prior antigen experience (Fig. 3, A and B). Adult frequencies of SARS-CoV-2 convergent clones were lower in blood and lymphoid tissues compared to children's blood, with few CS examples (Fig. 3A and fig. S9). Convergent clones specific for SARS-CoV-2 receptor-binding domain (RBD) and other S domains showed similar distributions (fig. S10). Reference antibodies for SARS-CoV-2, EBOV, and the pathogens in Fig. 1 used a wide diversity of IGHV genes (fig. S11).

Three convergent clones from five children but no adults in this study had IGH sequences highly similar to SARS-CoV-2 S-binding clones isolated from a pre-pandemic donor that were reported to weakly bind other HCoV spikes (26) (Fig. 3C). Three other clones from six children had IGHs identical to known SARS-CoV-2 binders (fig. S12). We expressed 19 monoclonal antibody (mAb) clones for SARS-CoV-2 (table S5) with IGH from participants in this study and reference light chains, and identified 17 binders for SARS-CoV-2 S and S domains (Table 1). Four RBD-binders showed over 90% blocking of ACE2 binding to SARS-CoV-2 S (table S6). mAb FY11H1 showed evidence of S2 binding and did not block ACE2 binding. We characterized the breadth of mAb binding using a panel of HCoV spikes and SARS-CoV-2 viral variant RBDs and spikes. Three child-derived mAbs (FY7H1, FY7H2, and FY1H2) and one adult mAb (FY4H1) showed the strongest binding to B.1.1.7, B.1.351, and P.1 S and RBD variants (table S7). Cross-reactive binding to endemic HCoV spikes was very weak to negative for all mAbs, as previously noted for reference mAb-154 (similar to mAb FY13H1) isolated from a sorted cross-reactive B cell (26). The child-derived mAbs FY13H1 and FY9H2 had higher although still weak signal for binding HKU1. Thus, children's convergent coronavirus-binding B cells may have greater cross-reactivity compared to those of

adults, in addition to having higher frequencies.

Childhood immune responses are particularly important in an individual's life, as they form the initial memory B cell pool that shapes future responses (29). We find that in comparison to adults, children have higher frequencies of convergent B cell clones in their blood for pathogens they have encountered. Notably, pre-pandemic children also had class-switched convergent clones to SARS-CoV-2 and its viral variants, but not EBOV, at higher frequencies than adults. We hypothesize that previous HCoV exposures may stimulate cross-reactive memory, and that such clonal responses may have their highest frequencies in childhood. Caveats of our analysis are that convergent clones may not fully represent the properties of all pathogen-specific clones in an individual, and binding affinities for cross-reactivity that would be relevant in vivo are not known. Further study of the role of cross-reactive memory B cell populations in primary immune responses to related but divergent viruses, as well as better understanding of the determinants of long-lived B cell memory and plasma cell formation will be important for ongoing improvement of vaccines to SARS-CoV-2, its viral variants, and other pathogens.

REFERENCES AND NOTES

1. S. D. Boyd, J. E. Crowe Jr., Deep sequencing and human antibody repertoire analysis. *Curr. Opin. Immunol.* **40**, 103–109 (2016). [doi:10.1016/j.coi.2016.03.008](https://doi.org/10.1016/j.coi.2016.03.008) [Medline](#)
2. D. D. Dudley, J. Chaudhuri, C. H. Bassing, F. W. Alt, Mechanism and control of V(D)J recombination versus class switch recombination: Similarities and differences. *Adv. Immunol.* **86**, 43–112 (2005). [doi:10.1016/S0065-2776\(04\)86002-4](https://doi.org/10.1016/S0065-2776(04)86002-4) [Medline](#)
3. K. J. Jackson, Y. Liu, K. M. Roskin, J. Glanville, R. A. Hoh, K. Seo, E. L. Marshall, T. C. Gurley, M. A. Moody, B. F. Haynes, E. B. Walter, H.-X. Liao, R. A. Albrecht, A. Garcia-Sastre, J. Chaparro-Riggers, A. Rajpal, J. Pons, B. B. Simen, B. Hanczaruk, C. L. Dekker, J. Laserson, D. Koller, M. M. Davis, A. Z. Fire, S. D. Boyd, Human responses to influenza vaccination show seroconversion signatures and convergent antibody rearrangements. *Cell Host Microbe* **16**, 105–114 (2014). [doi:10.1016/j.chom.2014.05.013](https://doi.org/10.1016/j.chom.2014.05.013) [Medline](#)
4. J. Trück, M. N. Ramasamy, J. D. Galson, R. Rance, J. Parkhill, G. Lunter, A. J. Pollard, D. F. Kelly, Identification of antigen-specific B cell receptor sequences using public repertoire analysis. *J. Immunol.* **194**, 252–261 (2015). [doi:10.4049/jimmunol.1401405](https://doi.org/10.4049/jimmunol.1401405) [Medline](#)
5. I. Setliff, W. J. McDonnell, N. Raju, R. G. Bombardi, A. A. Murji, C. Scheepers, R. Ziki, C. Mynhardt, B. E. Shepherd, A. A. Mamchak, N. Garrett, S. A. Karim, S. A. Mallal, J. E. Crowe Jr., L. Morris, I. S. Georgiev, Multi-donor longitudinal antibody repertoire sequencing reveals the existence of public antibody clonotypes in HIV-1 infection. *Cell Host Microbe* **23**, 845–854.e6 (2018). [doi:10.1016/j.chom.2018.05.001](https://doi.org/10.1016/j.chom.2018.05.001) [Medline](#)
6. L. Goo, V. Chohan, R. Nduati, J. Overbaugh, Early development of broadly neutralizing antibodies in HIV-1-infected infants. *Nat. Med.* **20**, 655–658 (2014). [doi:10.1038/nm.3565](https://doi.org/10.1038/nm.3565) [Medline](#)
7. F. Götzinger, B. Santiago-García, A. Noguera-Julián, M. Lanaspa, L. Lancella, F. I. Calò Carducci, N. Gabrovská, S. Velizarova, P. Prunk, V. Osterman, U. Krivec, A. Lo Vecchio, D. Shingadia, A. Soriano-Arandes, S. Melendo, M. Lanari, L. Pierantoni, N. Wagner, A. G. L'Huillier, U. Heininger, N. Ritz, S. Bandi, N. Krajcar, S. Roglić, M. Santos, C. Christiaens, M. Creuven, D. Buonsenso, S. B. Welch, M. Bogyi, F. Brinkmann, M. Tebruegge; ptbnet COVID-19 Study Group, COVID-19 in children and adolescents in Europe: A multinational, multicentre cohort study. *Lancet Child Adolesc. Health* **4**, 653–661 (2020). [doi:10.1016/S2352-4642\(20\)30177-2](https://doi.org/10.1016/S2352-4642(20)30177-2) [Medline](#)
8. X. Lu, L. Zhang, H. Du, J. Zhang, Y. Y. Li, J. Qu, W. Zhang, Y. Wang, S. Bao, Y. Li, C. Wu, H. Liu, D. Liu, J. Shao, X. Peng, Y. Yang, Z. Liu, Y. Xiang, F. Zhang, R. M. Silva, K. E. Pinkerton, K. Shen, H. Xiao, S. Xu, G. W. K. Wong; Chinese Pediatric Novel Coronavirus Study Team, SARS-CoV-2 infection in children. *N. Engl. J. Med.* **382**, 1663–1665 (2020). [doi:10.1056/NEJM2005073](https://doi.org/10.1056/NEJM2005073) [Medline](#)
9. C. Jiehao, X. Jin, L. Daojiong, Y. Zhi, X. Lei, Q. Zhenghai, Z. Yuehua, Z. Hua, J. Ran, L. Pengcheng, W. Xiangshi, G. Yanling, X. Aimei, T. He, C. Hailing, W. Chuning, L. Jingjing, W. Jianshe, Z. Mei, A case series of children with 2019 novel coronavirus infection: Clinical and epidemiological features. *Clin. Infect. Dis.* **71**, 1547–1551 (2020). [doi:10.1093/cid/ciaa198](https://doi.org/10.1093/cid/ciaa198) [Medline](#)
10. I. Liguoro, C. Pilotto, M. Bonanni, M. E. Ferrari, A. Pusiolo, A. Nocerino, E. Vidal, P. Cogo, SARS-CoV-2 infection in children and newborns: A systematic review. *Eur. J. Pediatr.* **179**, 1029–1046 (2020). [doi:10.1007/s00431-020-03684-7](https://doi.org/10.1007/s00431-020-03684-7) [Medline](#)
11. R. Carsetti, C. Quintarelli, I. Quinti, E. Piano Mortari, A. Zumla, G. Ippolito, F. Locatelli, The immune system of children: The key to understanding SARS-CoV-2 susceptibility? *Lancet Child Adolesc. Health* **4**, 414–416 (2020). [doi:10.1016/S2352-4642\(20\)30135-8](https://doi.org/10.1016/S2352-4642(20)30135-8) [Medline](#)
12. K. W. Ng, N. Faulkner, G. H. Cornish, A. Rosa, R. Harvey, S. Hussain, R. Ulferts, C. Earl, A. G. Wrobel, D. J. Benton, C. Roustian, W. Bolland, R. Thompson, A. Agua-Doce, P. Hobson, J. Heaney, H. Rickman, S. Paraskevopoulou, C. F. Houlihan, K. Thomson, E. Sanchez, G. Y. Shin, M. J. Spyder, D. Joshi, N. O'Reilly, P. A. Walker, S. Kjaer, A. Riddell, C. Moore, B. R. Jebson, M. Wilkinson, L. R. Marshall, E. C. Rosser, A. Radziszewska, H. Peckham, C. Ciurtin, L. R. Wedderburn, R. Beale, C. Swanton, S. Gandhi, B. Stockinger, J. McCauley, S. J. Gamblin, L. E. McCoy, P. Cherepanov, E. Nastouli, G. Kassiotis, Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. *Science* **370**, 1339–1343 (2020). [doi:10.1126/science.abe1107](https://doi.org/10.1126/science.abe1107) [Medline](#)
13. S. P. Weisberg, T. J. Connors, Y. Zhu, M. R. Baldwin, W.-H. Lin, S. Wontakal, P. A. Szabo, S. B. Wells, P. Dogra, J. Gray, E. Idzikowski, D. Stelitano, F. T. Bover, J. Davis-Porada, R. Matsumoto, M. M. L. Poon, M. Chait, C. Mathieu, B. Horvat, D. Decimo, K. E. Hudson, F. D. Zotti, Z. C. Bitan, F. La Carpija, S. A. Ferrara, E. Mace, J. Milner, A. Moscona, E. Hod, M. Porotto, D. L. Farber, Distinct antibody responses to SARS-CoV-2 in children and adults across the COVID-19 clinical spectrum. *Nat. Immunol.* **22**, 25–31 (2021). [doi:10.1038/s41590-020-00826-9](https://doi.org/10.1038/s41590-020-00826-9) [Medline](#)
14. C. Berek, C. Milstein, Mutation drift and repertoire shift in the maturation of the immune response. *Immunol. Rev.* **96**, 23–41 (1987). [doi:10.1111/j.1600-065X.1987.tb00507.x](https://doi.org/10.1111/j.1600-065X.1987.tb00507.x) [Medline](#)
15. J. Jacob, G. Kelsoe, K. Rajewsky, U. Weiss, Intracloonal generation of antibody mutants in germinal centres. *Nature* **354**, 389–392 (1991). [doi:10.1038/354389a0](https://doi.org/10.1038/354389a0) [Medline](#)
16. C. G. Vinuesa, C. de Lucas, M. C. Cook, Clinical implications of the specialised B cell response to polysaccharide encapsulated pathogens. *Postgrad. Med. J.* **77**, 562–569 (2001). [doi:10.1136/pmj.77.911.562](https://doi.org/10.1136/pmj.77.911.562) [Medline](#)
17. I. C. MacLennan, Y. J. Liu, Marginal zone B cells respond both to polysaccharide antigens and protein antigens. *Res. Immunol.* **142**, 346–351 (1991). [doi:10.1016/0923-2494\(91\)90089-2](https://doi.org/10.1016/0923-2494(91)90089-2) [Medline](#)
18. S. C. A. Nielsen, K. M. Roskin, K. J. L. Jackson, S. A. Joshi, P. Nejad, J.-Y. Lee, L. E. Wagar, T. D. Pham, R. A. Hoh, K. D. Nguyen, H. Y. Tsunemoto, S. B. Patel, R. Tibshirani, C. Ley, M. M. Davis, J. Parsonnet, S. D. Boyd, Shaping of infant B cell receptor repertoires by environmental factors and infectious disease. *Sci. Transl. Med.* **11**, eaat2004 (2019). [doi:10.1126/scitranslmed.aat2004](https://doi.org/10.1126/scitranslmed.aat2004) [Medline](#)
19. S. R. Dunn, A. B. Ryder, S. J. Tollefson, M. Xu, B. R. Saville, J. V. Williams, Seroepidemiologies of human metapneumovirus and respiratory syncytial virus in young children, determined with a new recombinant fusion protein enzyme-linked immunosorbent assay. *Clin. Vaccine Immunol.* **20**, 1654–1656 (2013). [doi:10.1128/CVI.00750-12](https://doi.org/10.1128/CVI.00750-12) [Medline](#)
20. M. P. Broderick, D. J. Faix, C. J. Hansen, P. J. Blair, Trends in meningococcal disease in the United States military, 1971–2010. *Emerg. Infect. Dis.* **18**, 1430–1437 (2012). [doi:10.3201/eid1809.120257](https://doi.org/10.3201/eid1809.120257) [Medline](#)
21. W. Meng, B. Zhang, G. W. Schwartz, A. M. Rosenfeld, D. Ren, J. J. C. Thome, D. J. Carpenter, N. Matsuoka, H. Lerner, A. L. Friedman, T. Granot, D. L. Farber, M. J. Shlomchik, U. Hershberg, E. T. Luning Prak, An atlas of B-cell clonal distribution in the human body. *Nat. Biotechnol.* **35**, 879–884 (2017). [doi:10.1038/nbt.3942](https://doi.org/10.1038/nbt.3942) [Medline](#)

22. V. V. Ganusov, R. J. De Boer, Do most lymphocytes in humans really reside in the gut? *Trends Immunol.* **28**, 514–518 (2007). [doi:10.1016/j.it.2007.08.009](https://doi.org/10.1016/j.it.2007.08.009) [Medline](#)
23. M. Langeveld, L. E. Gamadia, I. J. ten Berge, T-lymphocyte subset distribution in human spleen. *Eur. J. Clin. Invest.* **36**, 250–256 (2006). [doi:10.1111/j.1365-2362.2006.01626.x](https://doi.org/10.1111/j.1365-2362.2006.01626.x) [Medline](#)
24. E. M. Anderson, E. C. Goodwin, A. Verma, C. P. Arevalo, M. J. Bolton, M. E. Weirick, S. Gouma, C. M. McAllister, S. R. Christensen, J. Weaver, P. Hicks, T. B. Manzoni, O. Oniyide, H. Ramage, D. Mathew, A. E. Baxter, D. A. Oldridge, A. R. Greenplate, J. E. Wu, C. Alanio, K. D'Andrea, O. Kuthuru, J. Dougherty, A. Pattekar, J. Kim, N. Han, S. A. Apostolidis, A. C. Huang, L. A. Vella, L. Kuri-Cervantes, M. B. Pampena, M. R. Betts, E. J. Wherry, N. J. Meyer, S. Cherry, P. Bates, D. J. Rader, S. E. Hensley; UPenn COVID Processing Unit, Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. *Cell* **184**, 1858–1864.e10 (2021). [doi:10.1016/j.cell.2021.02.010](https://doi.org/10.1016/j.cell.2021.02.010) [Medline](#)
25. S. Bunyavanich, A. Do, A. Vicencio, Nasal gene expression of angiotensin-converting enzyme 2 in children and adults. *JAMA* **323**, 2427–2429 (2020). [doi:10.1001/jama.2020.8707](https://doi.org/10.1001/jama.2020.8707) [Medline](#)
26. A. Z. Wec, D. Wrapp, A. S. Herbert, D. P. Maurer, D. Haslwanter, M. Sakharkar, R. K. Jangra, M. E. Dieterle, A. Lilov, D. Huang, L. V. Tse, N. V. Johnson, C.-L. Hsieh, N. Wang, J. H. Nett, E. Champney, I. Burnina, M. Brown, S. Lin, M. Sinclair, C. Johnson, S. Pudi, R. Bortz 3rd, A. S. Wirchnianski, E. Lauderlich, C. Florez, J. M. Fels, C. M. O'Brien, B. S. Graham, D. Nemazee, D. R. Burton, R. S. Baric, J. E. Voss, K. Chandran, J. M. Dye, J. S. McLellan, L. M. Walker, Broad neutralization of SARS-related viruses by human monoclonal antibodies. *Science* **369**, 731–736 (2020). [doi:10.1126/science.abc7424](https://doi.org/10.1126/science.abc7424) [Medline](#)
27. S. I. Kim, J. Noh, S. Kim, Y. Choi, D. K. Yoo, Y. Lee, H. Lee, J. Jung, C. K. Kang, K.-H. Song, P. G. Choe, H. B. Kim, E. S. Kim, M.-J. Kim, M.-W. Seong, W. B. Park, M. D. Oh, S. Kwon, J. Chung, Stereotypic neutralizing V_H antibodies against SARS-CoV-2 spike protein receptor binding domain in patients with COVID-19 and healthy individuals. *Sci. Transl. Med.* **13**, eabd6990 (2021). [doi:10.1126/scitranslmed.abd6990](https://doi.org/10.1126/scitranslmed.abd6990) [Medline](#)
28. G. Song, W.-T. He, S. Callaghan, F. Anzanello, D. Huang, J. Ricketts, J. L. Torres, N. Beutler, L. Peng, S. Vargas, J. Cassell, M. Parren, L. Yang, C. Ignacio, D. M. Smith, J. E. Voss, D. Nemazee, A. B. Ward, T. Rogers, D. R. Burton, R. Andrabi, Cross-reactive serum and memory B cell responses to spike protein in SARS-CoV-2 and endemic coronavirus infection. *bioRxiv* 2020.09.22.308965 [Preprint]. 23 September 2020. <https://doi.org/10.1101/2020.09.22.308965>
29. C. P. Arevalo, V. Le Sage, M. J. Bolton, T. Eilola, J. E. Jones, K. A. Kormuth, E. Nturi, A. Balmaseda, A. Gordon, S. S. Lakdawala, S. E. Hensley, Original antigenic sin priming of influenza virus hemagglutinin stalk antibodies. *Proc. Natl. Acad. Sci. U.S.A.* **117**, 17221–17227 (2020). [doi:10.1073/pnas.1920321117](https://doi.org/10.1073/pnas.1920321117) [Medline](#)
30. K. M. Roskin, N. Simchoni, Y. Liu, J.-Y. Lee, K. Seo, R. A. Hoh, T. Pham, J. H. Park, D. Furman, C. L. Dekker, M. M. Davis, J. A. James, K. C. Nadeau, C. Cunningham-Rundles, S. D. Boyd, IgH sequences in common variable immune deficiency reveal altered B cell development and selection. *Sci. Transl. Med.* **7**, 302ra135 (2015). [doi:10.1126/scitranslmed.aab1216](https://doi.org/10.1126/scitranslmed.aab1216) [Medline](#)
31. J. Ye, N. Ma, T. L. Madden, J. M. Ostell, IgBLAST: An immunoglobulin variable domain sequence analysis tool. *Nucleic Acids Res.* **41**, W34–W40 (2013). [doi:10.1093/nar/gkt382](https://doi.org/10.1093/nar/gkt382) [Medline](#)
32. M. P. Lefranc, IMGT, the international ImMunoGeneTics database. *Nucleic Acids Res.* **31**, 307–310 (2003). [doi:10.1093/nar/gkg085](https://doi.org/10.1093/nar/gkg085) [Medline](#)
33. C. Wang, Y. Liu, M. M. Cavanagh, S. Le Sau, Q. Qi, K. M. Roskin, T. J. Looney, J.-Y. Lee, V. Dixit, C. L. Dekker, G. E. Swan, J. J. Goronzy, S. D. Boyd, B-cell repertoire responses to varicella-zoster vaccination in human identical twins. *Proc. Natl. Acad. Sci. U.S.A.* **112**, 500–505 (2015). [doi:10.1073/pnas.1415875112](https://doi.org/10.1073/pnas.1415875112) [Medline](#)
34. M. P. Lefranc, V. Giudicelli, P. Duroux, J. Jabado-Michaloud, G. Folch, S. Aouinti, E. Carillon, H. Duvergey, A. Houles, T. Paysan-Lafosse, S. Hadi-Saljoqi, S. Sasorith, G. Lefranc, S. Kossida, IMGT®, the international ImMunoGeneTics information system® 25 years on. *Nucleic Acids Res.* **43**, D413–D422 (2015). [doi:10.1093/nar/gku1056](https://doi.org/10.1093/nar/gku1056) [Medline](#)
35. A. H. Lucas, G. R. McLean, D. C. Reason, A. P. O'Connor, M. C. Felton, K. D. Moulton, Molecular ontogeny of the human antibody repertoire to the *Haemophilus influenzae* type B polysaccharide: Expression of canonical variable regions and their variants in vaccinated infants. *Clin. Immunol.* **108**, 119–127 (2003). [doi:10.1016/S1521-6616\(03\)00094-9](https://doi.org/10.1016/S1521-6616(03)00094-9) [Medline](#)
36. E. E. Adderson, P. G. Shackelford, A. Quinn, P. M. Wilson, M. W. Cunningham, R. A. Insel, W. L. Carroll, Restricted immunoglobulin VH usage and VDJ combinations in the human response to *Haemophilus influenzae* type b capsular polysaccharide. Nucleotide sequences of monospecific anti-*Haemophilus* antibodies and polyspecific antibodies cross-reacting with self antigens. *J. Clin. Invest.* **91**, 2734–2743 (1993). [doi:10.1172/JCI116514](https://doi.org/10.1172/JCI116514) [Medline](#)
37. A. H. Lucas, J. W. Larrick, D. C. Reason, Variable region sequences of a protective human monoclonal antibody specific for the *Haemophilus influenzae* type b capsular polysaccharide. *Infect. Immun.* **62**, 3873–3880 (1994). [doi:10.1128/IAI.62.9.3873-3880.1994](https://doi.org/10.1128/IAI.62.9.3873-3880.1994) [Medline](#)
38. J. D. Berry, D. J. Boese, D. K. Law, W. D. Zollinger, R. S. Tsang, Molecular analysis of monoclonal antibodies to group variant capsular polysaccharide of *Neisseria meningitidis*: recurrent heavy chains and alternative light chain partners. *Mol. Immunol.* **42**, 335–344 (2005). [doi:10.1016/j.molimm.2004.09.002](https://doi.org/10.1016/j.molimm.2004.09.002) [Medline](#)
39. S. L. Smithson, N. Srivastava, W. A. Hutchins, M. A. Westerink, Molecular analysis of the heavy chain of antibodies that recognize the capsular polysaccharide of *Neisseria meningitidis* in hu-PBMC reconstituted SCID mice and in the immunized human donor. *Mol. Immunol.* **36**, 113–124 (1999). [doi:10.1016/S0161-5890\(99\)00024-3](https://doi.org/10.1016/S0161-5890(99)00024-3) [Medline](#)
40. W. A. Hutchins, A. R. Adkins, T. Kieber-Emmons, M. A. Westerink, Molecular characterization of a monoclonal antibody produced in response to a group C meningococcal polysaccharide peptide mimic. *Mol. Immunol.* **33**, 503–510 (1996). [doi:10.1016/0161-5890\(96\)00012-0](https://doi.org/10.1016/0161-5890(96)00012-0) [Medline](#)
41. Z. Chen, K. S. Cox, A. Tang, J. Roman, M. Fink, R. M. Kaufhold, L. Guan, A. Xie, M. A. Boddicker, D. McGuinness, X. Xiao, H. Li, J. M. Skinner, T. Verch, M. Retzlaff, K. A. Vora, Human monoclonal antibodies isolated from a primary pneumococcal conjugate vaccine demonstrate the expansion of an antigen-driven hypermutated memory B cell response. *BMC Infect. Dis.* **18**, 613 (2018). [doi:10.1186/s12879-018-3517-7](https://doi.org/10.1186/s12879-018-3517-7) [Medline](#)
42. K. Kolibab, S. L. Smithson, B. Rabquer, S. Khuder, M. A. Westerink, Immune response to pneumococcal polysaccharides 4 and 14 in elderly and young adults: Analysis of the variable heavy chain repertoire. *Infect. Immun.* **73**, 7465–7476 (2005). [doi:10.1128/IAI.73.11.7465-7476.2005](https://doi.org/10.1128/IAI.73.11.7465-7476.2005) [Medline](#)
43. K. Smith, J. J. Muther, A. L. Duke, E. McKee, N.-Y. Zheng, P. C. Wilson, J. A. James, Fully human monoclonal antibodies from antibody secreting cells after vaccination with Pneumovax®23 are serotype specific and facilitate opsonophagocytosis. *Immunobiology* **218**, 745–754 (2013). [doi:10.1016/j.imbio.2012.08.278](https://doi.org/10.1016/j.imbio.2012.08.278) [Medline](#)
44. A. S. Adler, R. A. Mizrahi, M. J. Spindler, M. S. Adams, M. A. Asensio, R. C. Edgar, J. Leong, R. Leong, L. Roalfe, R. White, D. Goldblatt, D. S. Johnson, Rare, high-affinity anti-pathogen antibodies from human repertoires, discovered using microfluidics and molecular genomics. *Mabs* **9**, 1282–1296 (2017). [doi:10.1080/19420862.2017.1371383](https://doi.org/10.1080/19420862.2017.1371383) [Medline](#)
45. B. J. DeKosky, G. C. Ippolito, R. P. Deschner, J. J. Lavinder, Y. Wine, B. M. Rawlings, N. Varadarajan, C. Giesecke, T. Dörner, S. F. Andrews, P. C. Wilson, S. P. Hunicke-Smith, C. G. Willson, A. D. Ellington, G. Georgiou, High-throughput sequencing of the paired human immunoglobulin heavy and light chain repertoire. *Nat. Biotechnol.* **31**, 166–169 (2013). [doi:10.1038/nbt.2492](https://doi.org/10.1038/nbt.2492) [Medline](#)
46. J. de Kruijff, A. Kramer, T. Visser, C. Clements, R. Nijhuis, F. Cox, V. van der Zande, R. Smit, D. Pinto, M. Throsby, T. Logtenberg, Human immunoglobulin repertoires against tetanus toxoid contain a large and diverse fraction of high-affinity promiscuous V_H genes. *J. Mol. Biol.* **387**, 548–558 (2009). [doi:10.1016/j.jmb.2009.02.009](https://doi.org/10.1016/j.jmb.2009.02.009) [Medline](#)
47. D. Frölich, C. Giesecke, H. E. Mei, K. Reiter, C. Daridon, P. E. Lipsky, T. Dörner, Secondary immunization generates clonally related antigen-specific plasma cells and memory B cells. *J. Immunol.* **185**, 3103–3110 (2010). [doi:10.4049/jimmunol.1000911](https://doi.org/10.4049/jimmunol.1000911) [Medline](#)
48. T. R. Poulsen, A. Jensen, J. S. Haurum, P. S. Andersen, Limits for antibody affinity maturation and repertoire diversification in hypervaccinated humans. *J. Immunol.* **187**, 4229–4235 (2011). [doi:10.4049/jimmunol.1000928](https://doi.org/10.4049/jimmunol.1000928) [Medline](#)
49. M. S. Gilman, C. A. Castellanos, M. Chen, J. O. Ngwuta, E. Goodwin, S. M. Moin, V. Mas, J. A. Melero, P. F. Wright, B. S. Graham, J. S. McLellan, L. M. Walker, Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. *Sci. Immunol.* **1**, eaaj1879 (2016). [doi:10.1126/sciimmunol.aaj1879](https://doi.org/10.1126/sciimmunol.aaj1879) [Medline](#)

50. J. V. Williams, J. H. Weitkamp, D. L. Blum, B. J. LaFleur, J. E. Crowe Jr., The human neonatal B cell response to respiratory syncytial virus uses a biased antibody variable gene repertoire that lacks somatic mutations. *Mol. Immunol.* **47**, 407–414 (2009). [doi:10.1016/j.molimm.2009.08.024](https://doi.org/10.1016/j.molimm.2009.08.024) [Medline](#)
51. A. Tang, Z. Chen, K. S. Cox, H.-P. Su, C. Callahan, A. Fridman, L. Zhang, S. B. Patel, P. J. Cejas, R. Swoyer, S. Touch, M. P. Citron, D. Govindarajan, B. Luo, M. Eddins, J. C. Reid, S. M. Soisson, J. Gallii, D. Wang, Z. Wen, G. J. Heidecker, D. R. Casimiro, D. J. DiStefano, K. A. Vora, A potent broadly neutralizing human RSV antibody targets conserved site IV of the fusion glycoprotein. *Nat. Commun.* **10**, 4153 (2019). [doi:10.1038/s41467-019-12137-1](https://doi.org/10.1038/s41467-019-12137-1) [Medline](#)
52. B. Cortjens, E. Yasuda, X. Yu, K. Wagner, Y. B. Claassen, A. Q. Bakker, J. B. M. van Woensel, T. Beaumont, Broadly reactive anti-respiratory syncytial virus G antibodies from exposed individuals effectively inhibit infection of primary airway epithelial cells. *J. Virol.* **91**, e02357-16 (2017). [doi:10.1128/JVI.02357-16](https://doi.org/10.1128/JVI.02357-16) [Medline](#)
53. E. Goodwin, M. S. A. Gilman, D. Wrapp, M. Chen, J. O. Ngwuta, S. M. Moin, P. Bai, A. Sivasubramanian, R. I. Connor, P. F. Wright, B. S. Graham, J. S. McLellan, L. M. Walker, Infants infected with respiratory syncytial virus generate potent neutralizing antibodies that lack somatic hypermutation. *Immunity* **48**, 339–349.e5 (2018). [doi:10.1016/j.immuni.2018.01.005](https://doi.org/10.1016/j.immuni.2018.01.005) [Medline](#)
54. J. C. Krause, T. Tsibane, T. M. Tumpey, C. J. Huffman, B. S. Briney, S. A. Smith, C. F. Basler, J. E. Crowe Jr., Epitope-specific human influenza antibody repertoires diversify by B cell intracellular sequence divergence and interclonal convergence. *J. Immunol.* **187**, 3704–3711 (2011). [doi:10.4049/jimmunol.1101823](https://doi.org/10.4049/jimmunol.1101823) [Medline](#)
55. M. A. Moody, R. Zhang, E. B. Walter, C. W. Woods, G. S. Ginsburg, M. T. McClain, T. N. Denny, X. Chen, S. Munshaw, D. J. Marshall, J. F. Whitesides, M. S. Drinker, J. D. Amos, T. C. Gurley, J. A. Eudailey, A. Foulger, K. R. DeRosa, R. Parks, R. R. Meyerhoff, J.-S. Yu, D. M. Kozink, B. E. Barefoot, E. A. Ramsburg, S. Khurana, H. Golding, N. A. Vandergrift, S. M. Alam, G. D. Tomaras, T. B. Kepler, G. Kelsoe, H.-X. Liao, B. F. Haynes, H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination. *PLOS ONE* **6**, e25797 (2011). [doi:10.1371/journal.pone.0025797](https://doi.org/10.1371/journal.pone.0025797) [Medline](#)
56. J. Wrammert, D. Koutsonanos, G.-M. Li, S. Edupuganti, J. Sui, M. Morrissey, M. McCausland, I. Skountzou, M. Hornig, W. I. Lipkin, A. Mehta, B. Razavi, C. Del Rio, N.-Y. Zheng, J.-H. Lee, M. Huang, Z. Ali, K. Kaur, S. Andrews, R. R. Amara, Y. Wang, S. R. Das, C. D. O'Donnell, J. W. Yewdell, K. Subbarao, W. A. Marasco, M. J. Mulligan, R. Compans, R. Ahmed, P. C. Wilson, Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. *J. Exp. Med.* **208**, 181–193 (2011). [doi:10.1084/jem.20101352](https://doi.org/10.1084/jem.20101352) [Medline](#)
57. A. H. Ellebedy, K. J. L. Jackson, H. T. Kissick, H. I. Nakaya, C. W. Davis, K. M. Roskin, A. K. McElroy, C. M. Oshansky, R. Elbein, S. Thomas, G. M. Lyon, C. F. Spiropoulou, A. K. Mehta, P. G. Thomas, S. D. Boyd, R. Ahmed, Defining antigen-specific plasmablast and memory B cell subsets in human blood after viral infection or vaccination. *Nat. Immunol.* **17**, 1226–1234 (2016). [doi:10.1038/ni.3533](https://doi.org/10.1038/ni.3533) [Medline](#)
58. K. E. Neu, J. J. Guthmiller, M. Huang, J. La, M. C. Vieira, K. Kim, N.-Y. Zheng, M. Cortese, M. E. Tepora, N. J. Hamel, K. T. Rojas, C. Henry, D. Shaw, C. L. Dulberger, B. Pulendran, S. Cobey, A. A. Khan, P. C. Wilson, Spec-seq unveils transcriptional subpopulations of antibody-secreting cells following influenza vaccination. *J. Clin. Invest.* **129**, 93–105 (2019). [doi:10.1172/JCI121341](https://doi.org/10.1172/JCI121341) [Medline](#)
59. Y. Liu, H.-X. Tan, M. Koutsakos, S. Jegaskanda, R. Esterbauer, D. Tilmanis, M. Aban, K. Kedzierska, A. C. Hurt, S. J. Kent, A. K. Wheatley, Cross-lineage protection by human antibodies binding the influenza B hemagglutinin. *Nat. Commun.* **10**, 324 (2019). [doi:10.1038/s41467-018-08165-y](https://doi.org/10.1038/s41467-018-08165-y) [Medline](#)
60. D. Hirano, N. Ohshima, R. Kubota-Koketsu, A. Yamasaki, G. Kurosawa, Y. Okuno, S. Yoshida, Y. Kurosawa, Three types of broadly reacting antibodies against influenza B viruses induced by vaccination with seasonal influenza viruses. *J. Immunol. Res.* **2018**, 7251793 (2018). [doi:10.1155/2018/7251793](https://doi.org/10.1155/2018/7251793) [Medline](#)
61. A. Yasuhara, S. Yamayoshi, P. Soni, T. Takenaga, C. Kawakami, E. Takashita, Y. Sakai-Tagawa, R. Uraki, M. Ito, K. Iwatsuki-Horimoto, T. Sasaki, K. Ikuta, S. Yamada, Y. Kawaoka, Diversity of antigenic mutants of influenza A(H1N1)pdm09 virus escaped from human monoclonal antibodies. *Sci. Rep.* **7**, 17735 (2017). [doi:10.1038/s41598-017-17986-8](https://doi.org/10.1038/s41598-017-17986-8) [Medline](#)
62. M. G. Joyce, A. K. Wheatley, P. V. Thomas, G.-Y. Chuang, C. Soto, R. T. Bailer, A. Druz, I. S. Georgiev, R. A. Gillespie, M. Kanekiyo, W.-P. Kong, K. Leung, S. N. Narpala, M. S. Prabhakaran, E. S. Yang, B. Zhang, Y. Zhang, M. Asokan, J. C. Boyington, T. Bylund, S. Darko, C. R. Lees, A. Ransier, C.-H. Shen, L. Wang, J. R. Whittle, X. Wu, H. M. Yassine, C. Santos, Y. Matsuoka, Y. Tsybovsky, U. Baxa, J. C. Mullikin, K. Subbarao, D. C. Douek, B. S. Graham, R. A. Koup, J. E. Ledgerwood, M. Roederer, L. Shapiro, P. D. Kwong, J. R. Mascola, A. B. McDermott; NISC Comparative Sequencing Program, Vaccine-induced antibodies that neutralize group 1 and group 2 influenza A viruses. *Cell* **166**, 609–623 (2016). [doi:10.1016/j.cell.2016.06.043](https://doi.org/10.1016/j.cell.2016.06.043) [Medline](#)
63. Y. Fu, Z. Zhang, J. Sheehan, Y. Avnir, C. Ridenour, T. Sachnik, J. Sun, M. J. Hossain, L.-M. Chen, Q. Zhu, R. O. Donis, W. A. Marasco, A broadly neutralizing anti-influenza antibody reveals ongoing capacity of haemagglutinin-specific memory B cells to evolve. *Nat. Commun.* **7**, 12780 (2016). [doi:10.1038/ncomms12780](https://doi.org/10.1038/ncomms12780) [Medline](#)
64. G. M. Li, C. Chiu, J. Wrammert, M. McCausland, S. F. Andrews, N.-Y. Zheng, J.-H. Lee, M. Huang, X. Qu, S. Edupuganti, M. Mulligan, S. R. Das, J. W. Yewdell, A. K. Mehta, P. C. Wilson, R. Ahmed, Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. *Proc. Natl. Acad. Sci. U.S.A.* **109**, 9047–9052 (2012). [doi:10.1073/pnas.1118979109](https://doi.org/10.1073/pnas.1118979109) [Medline](#)
65. A. Watanabe, K. R. McCarthy, M. Kuraoka, A. G. Schmidt, Y. Adachi, T. Onodera, K. Tonouchi, T. M. Caradonna, G. Bajic, S. Song, C. E. McGee, G. D. Sempowski, F. Feng, P. Urick, T. B. Kepler, Y. Takahashi, S. C. Harrison, G. Kelsoe, Antibodies to a conserved influenza head interface epitope protect by an IgG subtype-dependent mechanism. *Cell* **177**, 1124–1135.e16 (2019). [doi:10.1016/j.cell.2019.03.048](https://doi.org/10.1016/j.cell.2019.03.048) [Medline](#)
66. K. R. McCarthy, A. Watanabe, M. Kuraoka, K. T. Do, C. E. McGee, G. D. Sempowski, T. B. Kepler, A. G. Schmidt, G. Kelsoe, S. C. Harrison, Memory B cells that cross-react with group 1 and group 2 influenza A viruses are abundant in adult human repertoires. *Immunity* **48**, 174–184.e9 (2018). [doi:10.1016/j.immuni.2017.12.009](https://doi.org/10.1016/j.immuni.2017.12.009) [Medline](#)
67. S. F. Andrews, M. G. Joyce, M. J. Chambers, R. A. Gillespie, M. Kanekiyo, K. Leung, E. S. Yang, Y. Tsybovsky, A. K. Wheatley, M. C. Crank, J. C. Boyington, M. S. Prabhakaran, S. R. Narpala, X. Chen, R. T. Bailer, G. Chen, E. Coates, P. D. Kwong, R. A. Koup, J. R. Mascola, B. S. Graham, J. E. Ledgerwood, A. B. McDermott, Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans. *Sci. Immunol.* **2**, eaan2676 (2017). [doi:10.1126/sciimmunol.aan2676](https://doi.org/10.1126/sciimmunol.aan2676) [Medline](#)
68. P. J. M. Brouwer, T. G. Caniels, K. van der Straten, J. L. Snitselaar, Y. Aldon, S. Bangaru, J. L. Torres, N. M. A. Okba, M. Claireaux, G. Kerster, A. E. H. Bentlage, M. M. van Haaren, D. Guerra, J. A. Burger, E. E. Schermer, K. D. Verheul, N. van der Velde, A. van der Kooi, J. van Schooten, M. J. van Breemen, T. P. L. Bijl, K. Sliepen, A. Aartse, R. Derking, I. Bontjer, N. A. Kootstra, W. J. Wiersinga, G. Vidarsson, B. L. Haagmans, A. B. Ward, G. J. de Bree, R. W. Sanders, M. J. van Gils, Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability. *Science* **369**, 643–650 (2020). [doi:10.1126/science.abc5902](https://doi.org/10.1126/science.abc5902) [Medline](#)
69. T. F. Rogers, F. Zhao, D. Huang, N. Beutler, A. Burns, W. T. He, O. Limbo, C. Smith, G. Song, J. Woehl, L. Yang, R. K. Abbott, S. Callaghan, E. Garcia, J. Hurtado, M. Parren, L. Peng, S. Ramirez, J. Ricketts, M. J. Ricciardi, S. A. Rawlings, N. C. Wu, M. Yuan, D. M. Smith, D. Nemazee, J. R. Teijaro, J. E. Voss, I. A. Wilson, R. Andrabi, B. Briney, E. Landais, D. Sok, J. G. Jardine, D. R. Burton, Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model. *Science* **369**, 956–963 (2020). [doi:10.1126/science.abc7520](https://doi.org/10.1126/science.abc7520) [Medline](#)
70. S. J. Zost, P. Gilchuk, R. E. Chen, J. B. Case, J. X. Reidy, A. Trivette, R. S. Nargi, R. E. Sutton, N. Suryadevara, E. C. Chen, E. Binshtein, S. Shrihari, M. Ostrowski, H. Y. Chu, J. E. Didier, K. W. MacRenaris, T. Jones, S. Day, L. Myers, F. Eun-Hyung Lee, D. C. Nguyen, I. Sanz, D. R. Martinez, P. W. Rothlauf, L.-M. Bloyet, S. P. J. Whelan, R. S. Baric, L. B. Thackray, M. S. Diamond, R. H. Carnahan, J. E. Crowe Jr., Rapid isolation and profiling of a diverse panel of human monoclonal antibodies targeting the SARS-CoV-2 spike protein. *Nat. Med.* **26**, 1422–1427 (2020). [doi:10.1038/s41591-020-0998-x](https://doi.org/10.1038/s41591-020-0998-x) [Medline](#)
71. R. Shi, C. Shan, X. Duan, Z. Chen, P. Liu, J. Song, T. Song, X. Bi, C. Han, L. Wu, G. Gao, X. Hu, Y. Zhang, Z. Tong, W. Huang, W. J. Liu, G. Wu, B. Zhang, L. Wang, J. Qi, H. Feng, F.-S. Wang, Q. Wang, G. F. Gao, Z. Yuan, J. Yan, A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2. *Nature* **584**, 120–124 (2020). [doi:10.1038/s41586-020-2381-y](https://doi.org/10.1038/s41586-020-2381-y) [Medline](#)
72. E. Seydoux, L. J. Homad, A. J. MacCamy, K. R. Parks, N. K. Hurlburt, M. F. Jennewein, N. R. Akins, A. B. Stuart, Y. H. Wan, J. Feng, R. E. Nelson, S. Singh, K.

- W. Cohen, M. J. McElrath, J. A. Englund, H. Y. Chu, M. Pancera, A. T. McGuire, L. Stamatatos, Characterization of neutralizing antibodies from a SARS-CoV-2 infected individual. *bioRxiv* 2020.05.12.091298 [Preprint]. 12 May 2020. <https://doi.org/10.1101/2020.05.12.091298>.
73. D. F. Robbiani, C. Gaebler, F. Muecksch, J. C. C. Lorenzi, Z. Wang, A. Cho, M. Agudelo, C. O. Barnes, A. Gazumyan, S. Finkin, T. Hägglöf, T. Y. Oliveira, C. Viant, A. Hurley, H. H. Hoffmann, K. G. Millard, R. G. Kost, M. Cipolla, K. Gordon, F. Bianchini, S. T. Chen, V. Ramos, R. Patel, J. Dizon, I. Shimeliovich, P. Mendoza, H. Hartweger, L. Nogueira, M. Pack, J. Horowitz, F. Schmidt, Y. Weisblum, E. Michailidis, A. W. Ashbrook, E. Waltari, J. E. Pak, K. E. Huey-Tubman, N. Koranda, P. R. Hoffman, A. P. West Jr., C. M. Rice, T. Hatziioannou, P. J. Bjorkman, P. D. Bieniasz, M. Caskey, M. C. Nussenzweig, Convergent antibody responses to SARS-CoV-2 in convalescent individuals. *Nature* **584**, 437–442 (2020). [doi:10.1038/s41586-020-2456-9](https://doi.org/10.1038/s41586-020-2456-9) [Medline](#)
 74. D. Pinto, Y. J. Park, M. Beltramello, A. C. Walls, M. A. Tortorici, S. Bianchi, S. Jaconi, K. Culap, F. Zatta, A. De Marco, A. Peter, B. Guarino, R. Spreafico, E. Camerini, J. B. Case, R. E. Chen, C. Havenar-Daughton, G. Snell, A. Telenti, H. W. Virgin, A. Lanzavecchia, M. S. Diamond, K. Fink, D. Veasler, D. Corti, Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. *Nature* **583**, 290–295 (2020). [doi:10.1038/s41586-020-2349-y](https://doi.org/10.1038/s41586-020-2349-y) [Medline](#)
 75. C. Kreer, M. Zehner, T. Weber, M. S. Ercanoglu, L. Gieselmann, C. Rohde, S. Halwe, M. Korenkov, P. Schommers, K. Vanshylla, V. Di Cristanziano, H. Janicki, R. Brinker, A. Ashurov, V. Kräling, A. Kupke, H. Cohen-Dvashi, M. Koch, J. M. Eckert, S. Lederer, N. Pfeifer, T. Wolf, M. J. G. T. Vehreschild, C. Wendtner, R. Diskin, H. Gruell, S. Becker, F. Klein, Longitudinal isolation of potent near-germline SARS-CoV-2-neutralizing antibodies from COVID-19 patients. *Cell* **182**, 1663–1673 (2020). [doi:10.1016/j.cell.2020.08.046](https://doi.org/10.1016/j.cell.2020.08.046) [Medline](#)
 76. C. W. Davis, K. J. L. Jackson, A. K. McElroy, P. Halfmann, J. Huang, C. Chennareddy, A. E. Piper, Y. Leung, C. G. Albariño, I. Crozier, A. H. Ellebedy, J. Sidney, A. Sette, T. Yu, S. C. A. Nielsen, A. J. Goff, C. F. Spiropoulou, E. O. Saphire, G. Cavet, Y. Kawaoka, A. K. Mehta, P. J. Glass, S. D. Boyd, R. Ahmed, Longitudinal analysis of the human B cell response to Ebola virus infection. *Cell* **177**, 1566–1582.e17 (2019). [doi:10.1016/j.cell.2019.04.036](https://doi.org/10.1016/j.cell.2019.04.036) [Medline](#)
 77. P. Virtanen, R. Gommers, T. E. Oliphant, M. Haberland, T. Reddy, D. Cournapeau, E. Burovski, P. Peterson, W. Weckesser, J. Bright, S. J. van der Walt, M. Brett, J. Wilson, K. J. Millman, N. Mayorov, A. R. J. Nelson, E. Jones, R. Kern, E. Larson, C. J. Carey, I. Polat, Y. Feng, E. W. Moore, J. VanderPlas, D. Laxalde, J. Perktold, R. Cimrman, I. Henriksen, E. A. Quintero, C. R. Harris, A. M. Archibald, A. H. Ribeiro, F. Pedregosa, P. van Mulbregt, SciPy 1.0 Contributors, SciPy 1.0: Fundamental algorithms for scientific computing in Python. *Nat. Methods* **17**, 261–272 (2020). [doi:10.1038/s41592-019-0686-2](https://doi.org/10.1038/s41592-019-0686-2) [Medline](#)
 78. L. Fu, B. Niu, Z. Zhu, S. Wu, W. Li, CD-HIT: Accelerated for clustering the next-generation sequencing data. *Bioinformatics* **28**, 3150–3152 (2012). [doi:10.1093/bioinformatics/bts565](https://doi.org/10.1093/bioinformatics/bts565) [Medline](#)
 79. S. C. A. Nielsen, F. Yang, K. J. L. Jackson, R. A. Hoh, K. Röltgen, G. H. Jean, B. A. Stevens, J.-Y. Lee, A. Rustagi, A. J. Rogers, A. E. Powell, M. Hunter, J. Najeeb, A. R. Otrelo-Cardoso, K. E. Yost, B. Daniel, K. C. Nadeau, H. Y. Chang, A. T. Satpathy, T. S. Jardetzky, P. S. Kim, T. T. Wang, B. A. Pinsky, C. A. Blish, S. D. Boyd, Human B cell clonal expansion and convergent antibody responses to SARS-CoV-2. *Cell Host Microbe* **28**, 516–525.e5 (2020). [doi:10.1016/j.chom.2020.09.002](https://doi.org/10.1016/j.chom.2020.09.002) [Medline](#)
 80. W. McKinney, “Data structures for statistical computing in Python,” Proceedings of the 9th Python in Science Conference, Austin, Texas, 28 June to 3 July 2010.
 81. R Development Core Team, R: A Language and Environment for Statistical Computing (R Foundation for Statistical Computing, Vienna, Austria, 2010); <http://www.R-project.org>.
 82. R. A. Ehling, C. R. Weber, D. M. Mason, S. Friedensohn, B. Wagner, F. Bieberich, E. Kapetanovic, R. Vazquez-Lombardi, R. B. Di Roberto, K.-L. Hong, C. Wagner, C. J. Sheward, B. Murrell, A. Yermanos, A. P. Cuny, M. Savic, F. Rudolf, S. T. Reddy, Single-cell sequencing of plasma cells from COVID-19 patients reveals highly expanded clonal lineages produce specific and neutralizing antibodies to SARS-CoV-2. *bioRxiv* 2021.02.12.430940 [Preprint]. 12 February 2021. <https://doi.org/10.1101/2021.02.12.430940>.
 83. D. Li, R. J. Edwards, K. Manne, D. R. Martinez, A. Schäfer, S. M. Alam, K. Wiehe, X. Lu, R. Parks, L. L. Sutherland, T. H. Oguin III, C. McDanal, L. G. Perez, K. Mansouri, S. M. C. Gobeil, K. Janowska, V. Stalls, M. Kopp, F. Cai, E. Lee, A. Foulger, G. E. Hernandez, A. Sanzone, K. Tilahun, C. Jiang, L. V. Tse, K. W. Bock, M. Minai, B. M. Nagata, K. Cronin, V. Gee-Lai, M. Deyton, M. Barr, T. Von Holle, A. N. Macintyre, E. Stover, J. Feldman, B. M. Hauser, T. M. Caradonna, T. D. Scobey, W. Rountree, Y. Wang, M. A. Moody, D. W. Cain, C. T. DeMarco, T. N. Denny, C. W. Woods, E. W. Petzold, A. G. Schmidt, I.-T. Teng, T. Zhou, P. D. Kwong, J. R. Mascola, B. S. Graham, I. N. Moore, R. Seder, H. Andersen, M. G. Lewis, D. C. Montefiori, G. D. Sempowski, R. S. Baric, P. Acharya, B. F. Haynes, K. O. Saunders, The functions of SARS-CoV-2 neutralizing and infection-enhancing antibodies in vitro and in mice and nonhuman primates. *bioRxiv* 2020.12.31.424729 [Preprint]. 18 February 2021. <https://doi.org/10.1101/2020.12.31.424729>.
 84. M. I. J. Raybould, A. Kovaltuk, C. Marks, C. M. Deane, CoV-AbDab: the coronavirus antibody database. *Bioinformatics* **10.1093/bioinformatics/btaa739** (2020). [doi:10.1093/bioinformatics/btaa739](https://doi.org/10.1093/bioinformatics/btaa739) [Medline](#)

ACKNOWLEDGMENTS

We thank all staff members of the California Transplant Donor Network (now Donor Network West), especially S. Swain, RN, MSN. We thank Dr. A. Z. Fire, Dr. E. A. Hope, and Dr. J. D. Merker for helpful discussions and contributions to the research. The authors thank Meso Scale Diagnostics for helpful collaboration and material support in this study. **Funding:** This work was supported by NIH/NIAID R01AI127877, R01AI130398, U19AI057229, U19AI090019 and NIH/NCI U54CA260517 (S.D.B.), NIH R01 HD063142 (J.P.), and an endowment from the Crown Family Foundation (S.D.B.). **Author contributions:** F.Y. and S.D.B. conceived of the project. F.Y., S.C.A.N., K.J.L.J., Y.L., and K.M.R. performed data analyses. F.Y., S.C.A.N., and S.D.B. verified the analyses. F.Y., S.C.A.N., R.A.H., K.R., E.H., O.F.W., G.H.J., R.S.O., E.M.O., J.-Y.L., K.N., and T.D.P. contributed to sample preparation and carried out the experiments. T.D.P., K.C.N., C.U.N., J.P., and S.D.B. provided samples and supported the project. F.Y., S.C.A.N., and S.D.B. wrote the initial manuscript. All authors provided critical feedback and contributed to the final manuscript. **Competing interests:** S.D.B.: Consulting for Regeneron; stock ownership in AbCellera Biologics; collaboration with Meso Scale Diagnostics. K.N.: Director of World Allergy Organization (WAO) Center of Excellence at Stanford, Advisor at Cour Pharma; Co-founder of Before Brands, Alladapt, Latitude, and IgGenix; National Scientific Committee member at Immune Tolerance Network (ITN) and National Institutes of Health (NIH) clinical research centers; DSMB member for NHLBI. **Data and materials availability:** All data are available in the main text or the supplementary materials. Previously generated IGH repertoire data are available with BioProject number PRJNA503602 (child dataset) and PRJNA491287 [114 healthy human adult dataset was previously reported (18)]. The IGH sequences for mAbs tested in this study were deposited in GenBank (MW821491 to MW821509). The IGH repertoire data for the deceased organ donors and the cord blood infant samples is in BioProject: PRJNA674610. This work is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. To view a copy of this license, visit <https://creativecommons.org/licenses/by/4.0/>. This license does not apply to figures/photos/artwork or other content included in the article that is credited to a third party; obtain authorization from the rights holder before using such material.

SUPPLEMENTARY MATERIALS

science.sciencemag.org/cgi/content/full/science.abf6648/DC1

Materials and Methods

Figs. S1 to S12

Tables S1 to S9

References (30–84)

MDAR Reproducibility Checklist

13 November 2020; accepted 7 April 2021

Published online 12 April 2021

10.1126/science.abf6648

Table 1. Convergent mAb binding data for SARS-CoV-2 spike, RBD, and nucleocapsid (N), and endemic HCoV spikes. Testing by electrochemiluminescence immunoassay in duplicate wells, with the average arbitrary unit per milliliter (AU/ml) values displayed in the table. Antibodies with binding signal at least five standard deviations above the average of negative control antibodies (Neg1 to Neg5) are listed.

mAb	CoV-2 S	CoV-2 RBD	CoV-2 S2	CoV-2 N	CoV S	HKU1 S	OC43 S	NL63 S	229E S	Source
FY1H3	161.84	132.42	0.12	2.42	4.62	0.22	0.30	0.30	0.22	Children
FY3H1	158.05	130.83	0.08	0.89	1.00	0.10	0.17	0.17	0.11	Both
FY3H3	153.27	123.26	0.26	6.33	2.91	0.38	0.69	0.61	0.45	Children
FY3H2	150.57	127.35	0.24	0.87	1.18	0.10	0.16	0.14	0.09	Adults
FY7H1	149.78	125.82	0.12	1.41	4.21	0.10	0.19	0.19	0.13	Children
FY1H2	148.44	119.56	2.39	1.92	18.00	0.47	0.63	0.58	0.50	Children
FY13H1	147.29	119.22	0.15	3.55	0.39	1.41	0.47	0.29	0.25	Children
FY7H2	146.59	120.11	0.06	1.94	4.29	0.24	0.15	0.16	0.12	Children
FY4H1	131.23	116.83	0.19	2.27	1.32	0.25	0.39	0.27	0.23	Adults
FY8H1	114.20	107.56	0.03	0.80	2.08	0.12	0.09	0.07	0.04	Adults
FY9H1	91.02	94.74	1.39	3.62	5.87	0.75	0.56	0.31	0.30	Children
FY11H1	79.65	41.41	13.59	0.78	44.62	0.13	0.09	0.06	0.12	Both
FY6H1	79.09	71.33	0.54	5.22	2.88	0.45	0.27	0.21	0.24	Both
FY14H1	78.73	63.10	3.91	2.43	9.56	0.30	0.45	0.35	0.29	Adults
FY5H1	69.60	45.71	0.33	3.27	1.71	0.49	0.50	0.25	0.23	Children
FY9H2	53.53	13.86	3.83	2.42	10.03	1.46	0.35	0.23	0.25	Children
FY10H1	9.96	8.69	0.02	0.18	0.27	0.02	0.08	0.02	0.02	Adults
Neg5	0.52	0.01	0.00	0.00	0.02	0.00	0.00	0.00	0.00	Controls
Neg4	1.63	0.02	0.00	0.90	0.09	0.01	0.00	0.00	0.00	Controls
Neg3	1.22	0.02	0.00	0.03	0.07	0.00	0.00	0.00	0.00	Controls
Neg2	1.37	0.02	0.00	0.02	0.08	0.01	0.00	0.00	0.00	Controls
Neg1	0.87	0.02	0.00	0.01	0.04	0.00	0.00	0.00	0.00	Controls

Fig. 1. Frequency, class-switching, and SHM of pathogen-specific convergent clones in children and adults. (A) Convergent clone frequencies for each pathogen, plotted on a square root scale. Ages in years; CB, cord blood. (B) Fractions of convergent clones expressing unmutated IgM/IgD, mutated IgM/IgD, class-switched, or combinations of these. Children have significantly higher fractions of class-switched convergent clones with mutated IgM/IgD clone members (colored in purple) than adults, ($P = 5.08 \times 10^{-32}$, 6.66×10^{-29} , 2.39×10^{-29} , 3.45×10^{-34} , and 1.71×10^{-41} for Hib, NM, PP, TT, and RSV, respectively, by Wilcoxon–Mann–Whitney (WMW) test). (C) Median IGHV-gene SHM frequencies of each convergent clone in participants of different ages indicated in years. SHM frequencies of convergent clones expressing IgG or IgA were lower in children than in adults ($P = 6.50 \times 10^{-13}$ and 1.96×10^{-8} , respectively, WMW test).

Fig. 3. Convergent clones for SARS-CoV-2 and EBOV. (A) Convergent clone frequencies on a square-root scale. CS and mutM/D convergent clone frequencies for SARS-CoV-2 are higher in children than adults ($P = 1.22 \times 10^{-13}$ and 0.0089, respectively, WMW test). (B) SHM frequencies of convergent clones for each isotype in participants of different ages (x axis). (C) CDR-H3 amino acid sequences of convergent IGH cross-reactive to SARS-CoV-2 and other HCoV-229E. Top row: CDR-H3 sequence logos for reported antigen-specific clones; Second row: sequence logos for convergent clones from children (blue indicates a match, cyan indicates sequence differences).